ReviewOncology research2024
Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.
Review in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inflammatory Myofibroblastic Tumour of Head and Neck: A Systematic Review Plus Meta-Analysis.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026Pooled it
- Clinicopathological Characteristics, Molecular Findings, and Survival of Lung Cancer in Adults Aged <30 Years in China: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- An unusual presentation of abdominopelvic inflammatory myofibroblastic tumor in an adolescent male: a rare case report.International journal of surgery case reports · 2026Article
- Article
- Autoimmune-Associated Pulmonary Inflammatory Myofibroblastic Tumour: A Diagnostic and Therapeutic Challenge.Respirology case reports · 2026Article
- Anterior Chest Wall Leiomyoma in a 4-Year-Old Girl: A Rare Pediatric Case.Clinical case reports · 2026Article
- Article
- A Rare Case of Pediatric Gastric Inflammatory Myofibroblastic Tumor (IMT) Mimicking Gastrointestinal Stromal Tumor (GIST): A Case Report.Clinical case reports · 2026Article
- Article
- Abdominal wall inflammatory myofibroblastic tumor initially misdiagnosed as leiomyoma: a rare case report.Journal of surgical case reports · 2026Article
- Primary Renal Mesenchymal Tumors: A Study from North India, Emphasizing Rare Entities and Molecular Profiles.Journal of kidney cancer and VHL · 2026Article
- Case Report: Dose-escalated volumetric modulated arc therapy achieving bowel and renal protection for large retroperitoneal inflammatory myofibroblastic tumor invading ureter and inferior vena cava.Frontiers in oncology · 2026Article
- Laparoscopic Hepatectomy for Hepatic Inflammatory Myofibroblastic Tumor: A Case Report.Surgical case reports · 2026Article
- Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance.Frontiers in oncology · 2026Review
- Renal inflammatory myofibroblastic tumor: a case report.Frontiers in oncology · 2026Article
- Case Report: Urachal inflammatory myofibroblastic tumor with bladder invasion.Frontiers in oncology · 2026Article
- NPLOC4 Constructs Tumor Immunosuppressive Microenvironment in Pan-cancer and Hepatocellular Carcinoma.Current medicinal chemistry · 2026Article
- Gastric inflammatory myofibroblastic tumor in adults: a case report and literature review.Frontiers in oncology · 2026Article
- Clinical features and prognosis of orbital inflammatory myofibroblastic tumor.International journal of ophthalmology · 2026Article
- Anaplastic lymphoma kinase-negative inflammatory myofibroblastic tumor of the appendix and ileocecal region: a rare clinical entity.Journal of surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.